Matthias Hubenthal
Overview
Explore the profile of Matthias Hubenthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tandon R, Harder I, Stolzl D, Hubenthal M, Sander N, Hartmann J, et al.
J Invest Dermatol
. 2024 Dec;
PMID: 39733934
Atopic dermatitis is characterized by a complex epidermal barrier deficiency and exaggerated immune responses dominated by type 2 mechanisms with variable contributions of additional immune axes. IL-13 is overexpressed in...
2.
Emmert H, Rademacher F, Hubenthal M, Glaser R, Norsgaard H, Weidinger S, et al.
JID Innov
. 2024 Oct;
5(1):100309.
PMID: 39385749
Keratinocytes (KCs) from healthy donors stimulated with type 2 cytokines are often used to experimentally study atopic dermatitis (AD) inflammatory responses. Owing to potential intrinsic alterations, it seems favorable to...
3.
Hubenthal M, Dai C, Brown S, Heinrich L, Kind B, Harder I, et al.
Br J Dermatol
. 2024 May;
191(4):637-639.
PMID: 38820224
No abstract available.
4.
Bohm R, Bruckmueller H, Oswald S, Hubenthal M, Kaehler M, Ehmke L, et al.
Clin Pharmacol Ther
. 2024 Apr;
116(1):204-216.
PMID: 38637968
Although great progress has been made in the fine-tuning of diplotypes, there is still a need to further improve the predictability of individual phenotypes of pharmacogenetically relevant enzymes. The aim...
5.
Fonfara M, Hartmann J, Stolzl D, Sander N, Harder I, Rodriguez E, et al.
J Eur Acad Dermatol Venereol
. 2024 Feb;
38(9):1769-1775.
PMID: 38421042
Background: Atopic dermatitis (AD) is the most common paediatric inflammatory skin disease. There are currently no robust biomarkers that could reliably predict its manifestation, and on the molecular level, it...
6.
Ramessur R, Dand N, Langan S, Saklatvala J, Fritzsche M, Holland S, et al.
Br J Dermatol
. 2024 Feb;
191(1):14-23.
PMID: 38419411
More severe atopic dermatitis and psoriasis are associated with a higher cumulative impact on quality of life, multimorbidity and healthcare costs. Proactive, early intervention in those most at risk of...
7.
Carreras-Badosa G, Maslovskaja J, Vaher H, Pajusaar L, Annilo T, Lattekivi F, et al.
Sci Rep
. 2022 Dec;
12(1):22645.
PMID: 36587063
Atopic dermatitis (AD) and psoriasis vulgaris (PV) are chronic inflammatory skin diseases with heterogeneous molecular backgrounds. MicroRNAs (miRNAs) contribute to either development or regulation of many immune system related diseases....
8.
Rosati E, Martini G, Pogorelyy M, Minervina A, Degenhardt F, Wendorff M, et al.
Gut
. 2022 Mar;
71(11):2194-2204.
PMID: 35264446
Objective: One of the current hypotheses to explain the proinflammatory immune response in IBD is a dysregulated T cell reaction to yet unknown intestinal antigens. As such, it may be...
9.
Mobus L, Rodriguez E, Harder I, Boraczynski N, Szymczak S, Hubenthal M, et al.
J Allergy Clin Immunol
. 2022 Feb;
150(2):385-395.
PMID: 35182548
Background: Few studies have analyzed the blood transcriptome in atopic dermatitis (AD). Objective: We explored blood transcriptomic features of moderate to severe AD. Methods: Blood messenger RNA sequencing on 60...
10.
Juzenas S, Hubenthal M, Lindqvist C, Kruse R, Steiert T, Degenhardt F, et al.
J Crohns Colitis
. 2022 Jan;
16(7):1097-1109.
PMID: 35022690
Background And Aims: Inflammatory bowel disease [IBD] is a chronic relapsing disorder of the gastrointestinal tract, which generally manifests as Crohn's disease [CD] or ulcerative colitis [UC]. These subtypes are...